Semax

Semax is a synthetic heptapeptide created at the Institute of Molecular Genetics of the Russian Academy of Sciences. As a derivative of the adrenocorticotropic hormone fragment ACTH(4-10), this molecule maintains the neurotropic properties of the original hormone while not triggering cortisol release from the adrenal cortex. This distinction in effects is the reason the compound has garnered ongoing interest in cognitive and neuroprotection studies.

Since its approval in Russia in 1994 for neurological conditions such as transient ischemic attack, stroke recovery, and cognitive disorders, Semax has emerged as one of the most thoroughly researched short-chain regulatory peptides in brain research globally. Laboratories throughout Europe, Asia, and North America have integrated this molecule into studies on learning, neuroplasticity, ischemic injury, and age-related cognitive decline.